Biomedical Engineering Reference
In-Depth Information
development of nano-based drug delivery systems for encapsulation and
release of antitiberculosis drugs [73]. Pandey
et al.
reported the formula-
tion of three anti-TB drugs i.e. RIF, INH, and PYZ encapsulated in PLG
nanoparticles. In
M. tuberculosis
infected mice, at er oral administration
of drug loaded nanoparticles at every 10
th
day, resulted in no detection of
the tubercle bacilli in the tissues at er 5 oral doses of treatment. h ese oral
nano based drug delivery of anti-TB drugs has resulted in reduction of
dosing frequency and better management of tuberculosis [20]. Prabakaran
developed an osmotically regulated capsular multi-drug oral delivery sys-
tem made of asymmetric membrane coating and dense semipermeable
membrane coating-capsular systems for the controlled administration of
RIF and INH for the treatment of TB [74]. Various anti-TB drugs have
been formulated in dry microparticles for pulmonary delivery of drugs.
h ese microparticles provided promising strategy in targeting those TB
sites, which can be directly administered to the lungs with reduced sys-
temic side ef ects.
According to the experiment three formulations of PLG (each encap-
sulating rifampicin) were developed i.e. non-porous (based on their drug
release behaviour), hardened (based on the use of polyvinyl
alcohol as a
hardening agent) and porous. Out of three, the hardened PLG microcap-
sules which showed 12-14% encapsulation of rifampicin and sustained
drug release for 42 days in all the organs can be used as controlled drug
delivery [75].
Nanoparticle with drug released
in blood capillary
Drug release on degradation
Endolytic
vesicle
Lysozyme
Release of nanoparticle encapsulated
drug into the infected macrophage
Blood capillary
Figure 14.6
Release of nanoparticles encapsulated drug into infected alveolar
macrophages of human.
